Page 44 - Read Online

19. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg alterations associated with hepatocellular carcinomas define
P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J. distinct path-ways of hepatocarcinogenesis. Gastroenterology
DNA damage response as a candidate anti-cancer barrier in early 2001;120:1763-73.
human tumorigenesis. Nature 2005;434:864-70. 32. Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, Zhou J, Li Y,
20. Wang Y, Hong Y, Li M, Long J, Zhao YP, Zhang JX, Li Q, You H, Sun J, Chen Y, Liang X, Zhao J, Pan K, Wang H, Xia J. Analysis of
Tong WM, Jia JD, Huang J. Mutation inactivation of Nijmegen loss of heterozygosity on chromosome 4q in hepatocellular carcinoma
breakage syndrome gene (NBS1) in hepatocellular carcinoma and using high-throughput SNP array. Oncol Rep 2010;23:445-55.
intrahepatic cholangiocarcinoma. PLoS One 2013;8:e82426. 33. Peng C, Zhang Z, Wu J, Lv Z, Tang J, Xie H, Zhou L, Zheng S.
21. Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, Ikeda K, A critical role for ZDHHC2 in metastasis and recurrence in human
Kumada H, Toyota J, Morizono T, Tsunoda T, Kubo M, Nakamura hepatocellular carcinoma. Biomed Res Int 2014;2014:832712.
Y, Kamatani N, Chayama K. Variation in the DEPDC5 locus is 34. Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, Kitaichi
associated with progression to hepatocellular carcinoma in chronic T, Yamada N, Iwai N, Nishikawa T, Yamaguchi K, Moriguchi M,
hepatitis C virus carriers. Nat Genet 2011;43:797-800. Sumida Y, Mitsuyoshi H, Tanaka S, Arii S, Itoh Y. EVI1, a target gene
22. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, Ma F, Huang W, Yu L, for amplification at 3q26, antagonizes transforming growth factor-β-
Yue W, Wang Z, Li P, Zhang Y, Liang R, Wei Z, Cui Y, Xie W, Cai mediated growth inhibition in hepatocellular carcinoma. Cancer Sci
M, Yu X, Yuan Y, Xia X, Zhang X, Yang H, Qiu W, Yang J, Gong 2015;106:929-37.
F, Chen M, Shen H, Lin D, Zeng YX, He F, Zhou G. Genome-wide 35. Yung MK, Lo KW, Yip CW, Chung GT, Tong CY, Cheung PF,
association study identifies 1p36.22 as a new susceptibility locus for Cheung TT, Poon RT, So S, Fan ST, Cheung ST. Copy number
hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat gain of granulin-epithelin precursor (GEP) at chromosome 17q21
Genet 2010;42:755-8. associates with overexpression in human liver cancer. BMC Cancer
23. Liang KH, Lin CC, Yeh CT. GALNT14 SNP as a potential predictor 2015;15:264.
of response to combination chemotherapy using 5-FU, mitoxantrone 36. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M,
and cisplatin in advanced HCC. Pharmacogenomics 2011;12:1061- Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC,
73. Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane
24. Yeh CT, Liang KH, Lin CC, Chang ML, Hsu CL, Hung CF. A single B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer
nucleotide polymorphism on the GALNT14 gene as an effective International Research Group. Adjuvant trastuzumab in HER2-
predictor of response to chemotherapy in advanced hepatocellular positive breast cancer. N Engl J Med 2011;365:1273-83.
carcinoma. Int J Cancer 2014;134:1214-24. 37. Bacaksiz A, Sahin FI, Bilezikci B, Yilmaz Z. Determination of
25. Guo X, Ba Y, Ma X, An J, Shang Y, Huang Q, Yang H, Chen Z, HER-2/ Neu status in hepatocellular carcinoma cases. Genet Test
Xing J. A meta-analysis of array-CGH studies implicates antiviral 2008;12:211-4.
immunity pathways in the development of hepatocellular carcinoma. 38. Panvichian R, Tantiwetrueangdet A, Angkathunyakul N,
PLoS One 2011;6:e28404. Leelaudomlipi S. TOP2A amplification and overexpression in
26. Tomlinson IP, Lambros MB, Roylance RR. Loss of heterozygosity hepatocellular carcinoma tissues. Biomed Res Int 2015;2015:381602.
analysis: practically and conceptually flawed? Genes Chromosomes 39. Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak
Cancer 2002;34:349-53. M, Szaumkessel M, Pelinska K, Kiwerska K, Tönnies H, Grenman
27. Lau SH, Guan XY. Cytogenetic and molecular genetic alterations in R, Figlerowicz M, Siebert R, Szyfter K, Jarmuz M. High resolution
hepatocellular carcinoma. Acta Pharmacol Sin. 2005;26:659-65. ArrayCGH and expression profiling identifies PTPRD and PCDH17/
28. Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes PCH68 as tumor suppressor gene candidates in laryngeal squamous
HP, Schirmacher P. Frequent genomic imbalances suggest commonly cell carcinoma. Genes Chromosomes Cancer 2011;50:154-66.
altered tumour genes in human hepatocarcinogenesis. Br J Cancer 40. Nalesnik MA, Tseng G, Ding Y, Xiang GS, Zheng ZL, Yu Y, Marsh
2001;85:697-704. JW, Michalopoulos GK, Luo JH. Gene deletions and amplifications
29. Rashid A, Wang JS, Qian GS, Lu BX, Hamilton SR, Groopman in human hepatocellular carcinomas: correlation with hepatocyte
JD. Genetic alterations in hepatocellular carcinomas: association growth regulation. Am J Pathol 2012;180:1495-508.
between loss of chromosome 4q and p53 gene mutations. Br J 41. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H,
Cancer 1999;80:59-66. Sanchez-Cespedes M, Minna JD, Yokota J. A catalog of genes
30. Zondervan PE, Wink J, Alers JC, IJzermans JN, Schalm SW, de homozygously deleted in human lung cancer and the candidacy of
Man RA, van Dekken H. Molecular cytogenetic evaluation of virus- PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer
associated and non-viral hepatocellular carcinoma: analysis of 26 2010;49:342-52.
carcinomas and 12 concurrent dysplasias. J Pathol 2000;192:207-15. 42. Acun T, Demir K, Oztas E, Arango D, Yakicier MC. PTPRD is
31. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, homozygously deleted and epigenetically downregulated in human
Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic hepatocellular carcinomas. OMICS 2015;19:220-9.

Hepatoma Research | Volume 2| Issue 2 | February 29, 2016 35